| 沈梦圆,费扬,王继政,孙丽琴.补肾活血法治疗糖尿病性骨质疏松症疗效及安全性的Meta分析[J].浙江中西医结合杂志,2022,32(1): |
| 补肾活血法治疗糖尿病性骨质疏松症疗效及安全性的Meta分析 |
| Efficacy and safety assessment of Bushen Huoxue Decoction for diabetic osteoporosis |
| 投稿时间：2021-02-27 修订日期：2021-11-12 |
| DOI： |
| 中文关键词: 补肾活血汤 糖尿病骨质疏松症 Meta分析 有效性 安全性 |
| 英文关键词:Bushen Huoxue Decoction Diabetic Osteoporosis Meta-analysis Efficacy Safety |
| 基金项目: |
|
| 摘要点击次数: 439 |
| 全文下载次数: 1 |
| 中文摘要: |
| ［摘要］目的：系统评价补肾活血汤治疗糖尿病性骨质疏松症的疗效和安全性。方法：计算机检索CBM，CNKI，WanFang Data，VIP，PubMed，The Cochrane Library，Embase，Web of Science、中国临床试验注册中心等多个数据库，检索时间选定为建库至2020年12月1日。筛选补肾活血汤治疗糖尿病性骨质疏松症的随机对照试验（Randomized Controlled Trial，RCT）。由两位录入员按纳入与排除标准独立筛选文献、提取资料并进行文献质量评价后，使用RevMan 5.3软件进行Meta分析，Stata 14.0软件进行Begger和Egger检验以评估发表偏倚。结果：共纳入21项随机临床试验。与对照组相比，补肾活血汤治疗糖尿病性骨质疏松症的总有效率提高，骨密度增高、中医证候评分增高、疼痛评分（Visual Analogue Score，VAS）降低、糖化血红蛋白降低。不良反应的发生没有统计学意义。发表偏倚检验结果显示总有效率不存在发表偏倚。结论：目前的证据表明，补肾活血汤治疗糖尿病性骨质疏松症具有显著的有效性和安全性，相比与常规治疗组，其不良反应的发生率没有统计学意义。由于纳入试验的数量有限、中药配方的差异以及方法学的局限性等多种因素，今后仍需要对补肾活血汤治疗糖尿病性骨质疏松症的临床应用进行更细致、更长期的观察。 |
| 英文摘要: |
| ［ABSTRACT］Objective: To systematically evaluate the efficacy and safety of Bushen Huoxue Decoction in the treatment of diabetic osteoporosis. Methods: CBM, CNKI, Wanfang Data, VIP, PubMed, The Cochrane Library, Embase, Web of Science, ChiCTR and other databases were retrieved by computer to obtain literature published before December 1, 2020. Randomized controlled trials (RCTs) were screened and extracted. Two researchers independently screened the literature, extracted the data, and evaluated the quality of the included literature according to the inclusion and exclusion criteria. RevMan 5.3 software was used for Meta-analysis, Stata 14.0 software was used for Begger and Egger's test to evaluate the publication bias. Results: A total of 21 randomized clinical trials were included. Compared with conventional western medicine therapy, the group of combination with Bushen Huoxue Decoction had a higher overall response rate, increased Bone Mineral Density (BHD), higher TCM syndromes score, lower Visual Analogue Score (VAS), and lower HbA1c, with statistically significant differences. The adverse reactions had no statistically significance. The occurrence of adverse reactions was not statistical significant. The results of the publication bias test showed that there was no publication bias in the total effective rate. Conclusions: Current evidence indicates that Bushen Huoxue Decoction has significant efficacy and safety in the treatment of diabetic osteoporosis, and the incidence of adverse reactions is not statistically significant compared with the conventional western medicine treatment group. Due to the limited number of included trials and methodological limitations, more detailed and long-term observation of the clinical application of Bushen Huoxue Decoction in the treatment of diabetic osteoporosis is still needed in the future. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
